CA-SCIENTIST.COM
18.6.2024 13:56:30 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that LIDE Biotech has successfully completed VERIF.i® on-site assessments at two of its China-based facilities—Shanghai and Xi’an. VERIF.i is Scientist.com’s on-site pre-assessment program that helps suppliers of regulated services demonstrate the quality and standards of their laboratories to both existing and prospective clients.
LIDE is an award-winning, translational medicine contract research organization (CRO) with over a decade of experience delivering preclinical drug evaluation services globally. In addition to offering innovations in oncology translational research and immune-oncology, LIDE has a collection of over 2,000 patient derived xenograft (PDX) models covering 50+ cancer types, of which 200+ are special drug resistant and/or genetically altered. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment.
“We’ve adopted the highest global operational standards at LIDE, ensuring our facilities and processes not only meet but surpass industry expectations,” stated Dr. Danyi Wen, President and CEO of LIDE Biotech. “VERIF.i is one more way to demonstrate our commitment to quality and compliance to our biotech and pharmaceutical clients globally.”
VERIF.i provides LIDE Biotech and other suppliers of regulated research services, including human biospecimen acquisition, animal studies and chemistry, manufacturing and controls (CMC) services, the opportunity to proactively communicate the quality and capabilities of their laboratories against pre-defined criteria developed specifically for the biopharma industry. Independent, third-party auditors carry out on-site inspections, the results of which can be shared with clients or used to improve lab operations.
“On-site assessments of laboratories have always been difficult to complete due to high costs and intensive resource and time requirements,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com. “VERIF.i provides a new and viable solution for marketplace sellers and buyers alike. It enables a high-quality supplier like LIDE to differentiate itself from its peers by sharing information about its facilities, personnel and processes. At the same time, it eliminates redundant work and ultimately saves both buyers and sellers time and money."
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/
About LIDE Biotech
LIDE biotech is committed to accelerating translation from pre-clinical to clinical for our clients. Our robust database of over 2000+ PDX, CDX, and cell line models is an industry-leading resource. Additionally, LIDE provides proprietary kits (small sample K-cell collection, conditional cell reprogramming, MiniPDX and IO-FIVE assays) that help clients streamline their studies. Most importantly, our hospital collaborations offer clients an unparalleled translational platform to leverage in their drug R&D journey. Our CRO services can be custom tailored or leveraged with out-of-the-box solutions, including in vitro and in vivo studies, 3D and organoid approaches, all supplemented with in-house bioinformatics and a parallel immuno-oncology platform.
Visit www.lidebiotech.com to learn more and follow updates on the LIDE Biotech LinkedIn page.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 5,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618429370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
The Estée Lauder Companies and Forest Essentials to Enter a New Chapter in Their Long-Term Partnership5.3.2026 06:45:00 CET | Press release
Following Minority Investment, The Estée Lauder Companies to Acquire Remaining Shares in Forest EssentialsMira Kulkarni to Continue to Oversee Brand with Headquarters Remaining in New DelhiThe Estée Lauder Companies Committed to Bringing Luxurious Ayurveda to the World The Estée Lauder Companies Inc. (NYSE: EL) announced today that it has entered into an agreement, subject to regulatory approvals, to acquire the remaining interests in Forest Essentials, the Indian beauty brand grounded in the science of modern Luxurious Ayurveda. Building on a trusted 18-year partnership, this milestone celebrates The Estée Lauder Companies’ long-term commitment to nurturing and growing this extraordinary Indian brand and to expanding its consumer reach globally. Today’s announcement reflects the company’s strong confidence in Forest Essentials’ highly trusted brand equity, its vertically integrated capabilities, and its sustainability ethos. The transaction is expected to close in the second half of c
Kinaxis Announces Departure of Chief Financial Officer4.3.2026 23:00:00 CET | Press release
Leadership change comes as strong financial performance and AI-driven market momentum underpins long-term strategic growth Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that Blaine Fitzgerald, Chief Financial Officer (CFO), has advisedof his intention to step down from his role to pursue a new career opportunity with a private company outside the supply chain software space. A search will begin for a new CFO immediately. Fitzgerald remains with the company as CFO through May 8, following the company’s first quarter 2026 earnings call, to support a smooth transition. “We are grateful for Blaine’s leadership and contributions over the past six years. He has played a key role in strengthening our financial foundation, building out the financial leadership team, and advancing our AI strategy. Thanks to the depth and capability of our Senior Leadership Team, we remain well-positioned for continued success as we begin the search for our next finance
IFF Declares Dividend for First Quarter 20264.3.2026 22:15:00 CET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 10, 2026 to shareholders of record as of March 20, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260304579613/en/
Armis Named a Leader for Second Consecutive Year in 2026 Gartner® Magic Quadrant™ for CPS Protection Platforms4.3.2026 16:12:00 CET | Press release
Armis CentrixTM leveraged by global organizations to manage cyber risk across their entire attack surface Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2026 Gartner Magic Quadrant for CPS Protection Platforms for the second consecutive year. “In an era of agentic AI, the security of our cyber-physical systems has become a strategic imperative for enterprises and governments globally; it is a pivotal pillar of global stability,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe this back-to-back recognition from Gartner reflects our continued commitment to helping organizations secure the complex, critical world of CPS and reinforces the strength of our unified, proactive platform approach. Our innovation pipeline, which is aligned with our customers' needs, will continue to prioritize protecting critical environments to keep society safe and secure.” Armis was named a Leader in this report among the 13 vendor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom